{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:05:51Z","timestamp":1794049551245,"version":"4.8.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Fibromyalgia is a common condition characterised by widespread chronic pain, associated with comorbid mental health disorders and reduced quality of life. Preclinical data suggest cannabis-based medicinal products (CBMPs) may have potential benefits in fibromyalgia, but there is a paucity of high-quality clinical evidence. This study aims to assess the change in patient-reported outcome measures (PROMs) and incidence of adverse events (AEs) in patients treated with CBMPs for fibromyalgia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This case series analysed data from the UK Medical Cannabis Registry (UKMCR). The primary outcome was change in PROMs [Fibromyalgia Symptom Severity, Fibromyalgia Widespread Pain Index, EQ-5D-5L, Generalised Anxiety Disorder-7, and Single-Item Sleep Quality Scale] from baseline to follow-up at 1, 3, 6, 12, and 18\u00a0months. Statistical significance was defined as\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.050.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Four hundred ninety-seven patients were included. The mean age was 44.66\u2009\u00b1\u200912.02\u00a0years, 341 patients (68.61%) were female, and the majority of patients were unemployed (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009268, 53.92%). There was an improvement in all PROMs (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.010) from baseline to all follow-up periods. Higher CBD doses (&gt;\u200925.00\u00a0mg\/day) and previous cannabis use were associated with increased odds of improvement on fibromyalgia-specific scales (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.050). 227 patients (45.67%) reported 2100 AEs (422.54%). Most AEs were mild-to-moderate (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091792, 85.33%). The most common AE was fatigue (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009153, 30.78%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There was an association between treatment with CBMPs and improvements in pain, anxiety, sleep, and general quality of life. The high incidence of AEs in relation to other patient cohorts from the UKMCR may relate to the central sensitisation mechanism of fibromyalgia.<\/jats:p>\n                    <jats:p>\n                      <jats:table-wrap>\n                        <jats:table>\n                          <jats:tbody>\n                            <jats:tr>\n                              <jats:td align=\"left\" colspan=\"2\">\n                                <jats:bold>Key Points<\/jats:bold>\n                                <jats:italic>\u2022 This study found that CBMPs were associated with short to medium-term improvements in pain, anxiety, sleep, and general quality-of-life in patients with fibromyalgia.<\/jats:italic>\n                                <jats:italic>\u2022 More randomised controlled trials are warranted to consolidate the literature, but this large analysis provides real-world data to inform their rollout.<\/jats:italic>\n                              <\/jats:td>\n                            <\/jats:tr>\n                          <\/jats:tbody>\n                        <\/jats:table>\n                      <\/jats:table-wrap>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10067-025-07846-6","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T10:39:07Z","timestamp":1765276747000},"page":"1927-1938","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["UK Medical Cannabis Registry: a case series analysing clinical outcomes of medicinal cannabis therapy for fibromyalgia"],"prefix":"10.1007","volume":"45","author":[{"given":"Madhur","family":"Varadpande","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Erridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arushika","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evonne","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"McLachlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Coomber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alia","family":"Darweish Medniuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Guru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Holden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Sajad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Searle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azfer","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Varma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Rucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Platt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5871-6501","authenticated-orcid":false,"given":"Mikael H.","family":"Sodergren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"issue":"3","key":"7846_CR1","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.semarthrit.2016.08.012","volume":"46","author":"F Wolfe","year":"2016","unstructured":"Wolfe F, Clauw DJ, Fitzcharles M, Goldenberg DL, H\u00e4user W, Katz RL et al (2016) 2016 revisions to the 2010\/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum 46(3):319\u2013329. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.08.012","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"7846_CR2","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/art.38905","volume":"67","author":"GT Jones","year":"2015","unstructured":"Jones GT, Atzeni F, Beasley M, Fl\u00fc\u00df E, Sarzi-Puttini P, Macfarlane GJ (2015) The prevalence of fibromyalgia in the general population: a comparison of the American College of Rheumatology 1990, 2010, and modified 2010 classification criteria. Arthritis Rheumatol 67(2):568\u2013575. https:\/\/doi.org\/10.1002\/art.38905","journal-title":"Arthritis Rheumatol"},{"issue":"18","key":"7846_CR3","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1007\/s40265-021-01602-1","volume":"81","author":"M Fitzcharles","year":"2021","unstructured":"Fitzcharles M, Petzke F, T\u00f6lle TR, H\u00e4user W (2021) Cannabis-based medicines and medical cannabis in the treatment of nociplastic pain. Drugs 81(18):2103\u20132116. https:\/\/doi.org\/10.1007\/s40265-021-01602-1","journal-title":"Drugs"},{"issue":"1","key":"7846_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1477-7525-9-71","volume":"9","author":"C Schaefer","year":"2011","unstructured":"Schaefer C, Chandran A, Hufstader M, Baik R, McNett M, Goldenberg D et al (2011) The comparative burden of mild, moderate and severe fibromyalgia: results from a cross-sectional survey in the United States. Health Qual Life Outcomes 9(1):71. https:\/\/doi.org\/10.1186\/1477-7525-9-71","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"7846_CR5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jpain.2010.01.002","volume":"11","author":"W H\u00e4user","year":"2010","unstructured":"H\u00e4user W, Petzke F, Sommer C (2010) Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain 11(6):505\u2013521. https:\/\/doi.org\/10.1016\/j.jpain.2010.01.002","journal-title":"J Pain"},{"issue":"1","key":"7846_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/ar4441","volume":"16","author":"W H\u00e4user","year":"2014","unstructured":"H\u00e4user W, Walitt B, Fitzcharles M, Sommer C (2014) Review of pharmacological therapies in fibromyalgia syndrome. Arthritis Res Ther 16(1):201. https:\/\/doi.org\/10.1186\/ar4441","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"7846_CR7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/papr.12743","volume":"19","author":"R Desai","year":"2019","unstructured":"Desai R, Jo A, Marlow NM (2019) Risk for medication nonadherence among Medicaid enrollees with fibromyalgia: development of a validated risk prediction tool. Pain Pract 19(3):295\u2013302. https:\/\/doi.org\/10.1111\/papr.12743","journal-title":"Pain Pract"},{"key":"7846_CR8","doi-asserted-by":"publisher","unstructured":"Pertwee RG (2006) Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 147(S1).\u00a0https:\/\/doi.org\/10.1038\/sj.bjp.0706406","DOI":"10.1038\/sj.bjp.0706406"},{"issue":"6690","key":"7846_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/28393","volume":"394","author":"A Calignano","year":"1998","unstructured":"Calignano A, La Rana G, Giuffrida A, Piomelli D (1998) Control of pain initiation by endogenous cannabinoids. Nature 394(6690):277\u2013281. https:\/\/doi.org\/10.1038\/28393","journal-title":"Nature"},{"issue":"2","key":"7846_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089432","volume":"9","author":"A Silvani","year":"2014","unstructured":"Silvani A, Berteotti C, Bastianini S, Lo Martire V, Mazza R, Pagotto U et al (2014) Multiple sleep alterations in mice lacking cannabinoid type 1 receptors. PLoS One 9(2):e89432. https:\/\/doi.org\/10.1371\/journal.pone.0089432","journal-title":"PLoS One"},{"issue":"4","key":"7846_CR11","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.mayocp.2023.12.018","volume":"99","author":"A Singla","year":"2024","unstructured":"Singla A, Anstine CV, Huang L, Rosedahl JK, Mohabbat AB, Philpot LM (2024) A cross-sectional survey study of cannabis use for fibromyalgia symptom management. Mayo Clin Proc 99(4):542\u2013550. https:\/\/doi.org\/10.1016\/j.mayocp.2023.12.018","journal-title":"Mayo Clin Proc"},{"key":"7846_CR12","doi-asserted-by":"publisher","unstructured":"Wang L, Hong PJ, May C, Rehman Y, Oparin Y, Hong CJ, et al (2021) Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials. BMJ n1034. https:\/\/doi.org\/10.1136\/bmj.n1034","DOI":"10.1136\/bmj.n1034"},{"key":"7846_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2040","author":"JW Busse","year":"2021","unstructured":"Busse JW, Vankrunkelsven P, Zeng L, Heen AF, Merglen A, Campbell F et al (2021) Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline. BMJ. https:\/\/doi.org\/10.1136\/bmj.n2040","journal-title":"BMJ"},{"issue":"3","key":"7846_CR14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1155\/2013\/918216","volume":"18","author":"M Fitzcharles","year":"2013","unstructured":"Fitzcharles M, Ste-Marie PA, Goldenberg DL, Pereira JX, Abbey S, Choini\u00e8re M et al (2013) 2012 Canadian guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary. Pain Res Manag 18(3):119\u2013126. https:\/\/doi.org\/10.1155\/2013\/918216","journal-title":"Pain Res Manag"},{"issue":"6","key":"7846_CR15","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.3390\/biomedicines11061621","volume":"11","author":"NH Strand","year":"2023","unstructured":"Strand NH, Maloney J, Kraus M, Wie C, Turkiewicz M, Gomez DA et al (2023) Cannabis for the treatment of fibromyalgia: a systematic review. Biomedicines 11(6):1621. https:\/\/doi.org\/10.3390\/biomedicines11061621","journal-title":"Biomedicines"},{"key":"7846_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcsop.2024.100524","volume":"16","author":"V Lopera","year":"2024","unstructured":"Lopera V, Restrepo JC, Amariles P (2024) Effectiveness and safety of cannabis-based products for medical use in patients with fibromyalgia syndrome: a systematic review. Explor Res Clin Soc Pharm 16:100524. https:\/\/doi.org\/10.1016\/j.rcsop.2024.100524","journal-title":"Explor Res Clin Soc Pharm"},{"issue":"2","key":"7846_CR17","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jpain.2007.09.002","volume":"9","author":"RQ Skrabek","year":"2008","unstructured":"Skrabek RQ, Galimova L, Ethans K, Perry D (2008) Nabilone for the treatment of pain in fibromyalgia. J Pain 9(2):164\u2013173. https:\/\/doi.org\/10.1016\/j.jpain.2007.09.002","journal-title":"J Pain"},{"issue":"10","key":"7846_CR18","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1093\/pm\/pnaa303","volume":"21","author":"C Chaves","year":"2020","unstructured":"Chaves C, Bittencourt PCT, Pelegrini A (2020) Ingestion of a THC-rich cannabis oil in people with fibromyalgia: a randomized, double-blind, placebo-controlled clinical trial. Pain Med 21(10):2212\u20132218. https:\/\/doi.org\/10.1093\/pm\/pnaa303","journal-title":"Pain Med"},{"issue":"2","key":"7846_CR19","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1213\/ANE.0b013e3181c76f70","volume":"110","author":"MA Ware","year":"2010","unstructured":"Ware MA, Fitzcharles M, Joseph L, Shir Y (2010) The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg 110(2):604\u2013610. https:\/\/doi.org\/10.1213\/ANE.0b013e3181c76f70","journal-title":"Anesth Analg"},{"issue":"4","key":"7846_CR20","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1097\/j.pain.0000000000001464","volume":"160","author":"T van de Donk","year":"2019","unstructured":"van de Donk T, Niesters M, Kowal MA, Olofsen E, Dahan A, van Velzen M (2019) An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. Pain 160(4):860\u2013869. https:\/\/doi.org\/10.1097\/j.pain.0000000000001464","journal-title":"Pain"},{"issue":"3","key":"7846_CR21","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1080\/14737175.2023.2181696","volume":"23","author":"L Bapir","year":"2023","unstructured":"Bapir L, Erridge S, Nicholas M, Pillai M, Dalavaye N, Holvey C et al (2023) Comparing the effects of medical cannabis for chronic pain patients with and without co-morbid anxiety: a cohort study. Expert Rev Neurother 23(3):281\u2013295. https:\/\/doi.org\/10.1080\/14737175.2023.2181696","journal-title":"Expert Rev Neurother"},{"key":"7846_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.3072","author":"C Wang","year":"2023","unstructured":"Wang C, Erridge S, Holvey C, Coomber R, Usmani A, Sajad M et al (2023) Assessment of clinical outcomes in patients with fibromyalgia: analysis from the UK Medical Cannabis Registry. Brain Behav. https:\/\/doi.org\/10.1002\/brb3.3072","journal-title":"Brain Behav"},{"issue":"1","key":"7846_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1080\/15360288.2024.2414073","volume":"39","author":"S Sridharan","year":"2025","unstructured":"Sridharan S, Erridge S, Holvey C, Coomber R, Holden W, Rucker JJ et al (2025) Comparison of cannabis-based medicinal product formulations for fibromyalgia: a cohort study. Journal of Pain & Palliative Care Pharmacotherapy 39(1):24\u201337. https:\/\/doi.org\/10.1080\/15360288.2024.2414073","journal-title":"Journal of Pain & Palliative Care Pharmacotherapy"},{"issue":"9596","key":"7846_CR24","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP (2007) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370(9596):1453\u20131457. https:\/\/doi.org\/10.1016\/S0140-6736(07)61602-X","journal-title":"Lancet"},{"key":"7846_CR25","unstructured":"Medicines & Healthcare products Regulatory Agency. The supply, manufacture, importation and distribution of unlicensed cannabis-based products for medicinal use in humans \u2018specials\u2019. https:\/\/assets.publishing.service.gov.uk\/media\/5e58eefb86650c53a363f77c\/Cannabis_Guidance__unlicensed_CBPMs__updated_2020.pdf. Accessed 10 Apr 2024"},{"issue":"1","key":"7846_CR26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000521288","volume":"91","author":"ME Charlson","year":"2022","unstructured":"Charlson ME, Carrozzino D, Guidi J, Patierno C (2022) Charlson comorbidity index: a critical review of clinimetric properties. Psychother Psychosom 91(1):8\u201335","journal-title":"Psychother Psychosom"},{"issue":"11","key":"7846_CR27","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1046\/j.1360-0443.2001.9611165311.x","volume":"96","author":"CM Bernaards","year":"2001","unstructured":"Bernaards CM, Twisk JWR, Snel J, Van Mechelen W, Kemper HCG (2001) Is calculating pack\u2010years retrospectively a valid method to estimate life\u2010time tobacco smoking? A comparison between prospectively calculated pack\u2010years and retrospectively calculated pack\u2010years. Addiction 96(11):1653\u20131661. https:\/\/doi.org\/10.1046\/j.1360-0443.2001.9611165311.x","journal-title":"Addiction"},{"issue":"3","key":"7846_CR28","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/npr2.12183","volume":"41","author":"S Erridge","year":"2021","unstructured":"Erridge S, Salazar O, Kawka M, Holvey C, Coomber R, Usmani A et al (2021) An initial analysis of the UK Medical Cannabis Registry: outcomes analysis of first 129 patients. Neuropsychopharmacol Rep 41(3):362\u2013370. https:\/\/doi.org\/10.1002\/npr2.12183","journal-title":"Neuropsychopharmacol Rep"},{"key":"7846_CR29","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE). https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf"},{"issue":"6","key":"7846_CR30","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3899\/jrheum.100594","volume":"38","author":"F Wolfe","year":"2011","unstructured":"Wolfe F, Clauw DJ, Fitzcharles M, Goldenberg DL, H\u00e4user W, Katz RS et al (2011) Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia. J Rheumatol 38(6):1113\u20131122. https:\/\/doi.org\/10.3899\/jrheum.100594","journal-title":"J Rheumatol"},{"key":"7846_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.999242","author":"C Merino-Soto","year":"2023","unstructured":"Merino-Soto C, Angulo-Ramos M, Rovira-Mill\u00e1n LV, Rosario-Hern\u00e1ndez E (2023) Psychometric properties of the generalized anxiety disorder-7 (GAD-7) in a sample of workers. Front Psychiatry. https:\/\/doi.org\/10.3389\/fpsyt.2023.999242","journal-title":"Front Psychiatry"},{"issue":"2","key":"7846_CR32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","volume":"9","author":"RH Dworkin","year":"2008","unstructured":"Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT et al (2008) Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 9(2):105\u2013121. https:\/\/doi.org\/10.1016\/j.jpain.2007.09.005","journal-title":"J Pain"},{"issue":"11","key":"7846_CR33","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.5664\/jcsm.7478","volume":"14","author":"E Snyder","year":"2018","unstructured":"Snyder E, Cai B, DeMuro C, Morrison MF, Ball W (2018) A new single-item sleep quality scale: results of psychometric evaluation in patients with chronic primary insomnia and depression. J Clin Sleep Med 14(11):1849\u20131857. https:\/\/doi.org\/10.5664\/jcsm.7478","journal-title":"J Clin Sleep Med"},{"key":"7846_CR34","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2025.2490539","author":"A Datta","year":"2025","unstructured":"Datta A, Erridge S, Warner-Levy J, Clarke E, McLachlan K, Coomber R et al (2025) UK medical cannabis registry: an updated clinical outcomes analysis of patients with post-traumatic stress disorder. Expert Rev Neurother. https:\/\/doi.org\/10.1080\/14737175.2025.2490539","journal-title":"Expert Rev Neurother"},{"issue":"4","key":"7846_CR35","doi-asserted-by":"publisher","DOI":"10.5041\/RMMJ.10129","volume":"4","author":"PG Fine","year":"2013","unstructured":"Fine PG, Rosenfeld MJ (2013) The endocannabinoid system, cannabinoids, and pain. Rambam Maimonides Med J 4(4):10.5041\/RMMJ.10129","journal-title":"Rambam Maimonides Med J"},{"issue":"6","key":"7846_CR36","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/ajad.13456","volume":"32","author":"Y Zhang-James","year":"2023","unstructured":"Zhang-James Y, Wyon E, Grapsas D, Johnson B (2023) Daily cannabis use may cause cannabis-induced hyperalgesia. Am J Addict 32(6):532\u2013538. https:\/\/doi.org\/10.1111\/ajad.13456","journal-title":"Am J Addict"},{"issue":"6","key":"7846_CR37","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.pmn.2020.07.003","volume":"21","author":"AR Pfalzgraf","year":"2020","unstructured":"Pfalzgraf AR, Lobo CP, Giannetti V, Jones KD (2020) Use of complementary and alternative medicine in fibromyalgia: results of an online survey. Pain Manag Nurs 21(6):516\u2013522. https:\/\/doi.org\/10.1016\/j.pmn.2020.07.003","journal-title":"Pain Manag Nurs"},{"issue":"7","key":"7846_CR38","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/s41386-022-01322-4","volume":"47","author":"S Nielsen","year":"2022","unstructured":"Nielsen S, Picco L, Murnion B, Winters B, Matheson J, Graham M et al (2022) Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies. Neuropsychopharmacology 47(7):1315\u20131330. https:\/\/doi.org\/10.1038\/s41386-022-01322-4","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"7846_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8060807","volume":"8","author":"I Sagy","year":"2019","unstructured":"Sagy I, Bar-Lev Schleider L, Abu-Shakra M, Novack V (2019) Safety and efficacy of medical cannabis in fibromyalgia. J Clin Med 8(6):807. https:\/\/doi.org\/10.3390\/jcm8060807","journal-title":"J Clin Med"},{"issue":"5","key":"7846_CR40","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/AJP.0b013e318208c8e4","volume":"27","author":"EM O\u2019Brien","year":"2011","unstructured":"O\u2019Brien EM, Waxenberg LB, Atchison JW, Gremillion HA, Staud RM, McCrae CS et al (2011) Intraindividual variability in daily sleep and pain ratings among chronic pain patients. Clin J Pain 27(5):425\u2013433. https:\/\/doi.org\/10.1097\/AJP.0b013e318208c8e4","journal-title":"Clin J Pain"},{"issue":"1","key":"7846_CR41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jbmt.2009.08.003","volume":"14","author":"GL Liptan","year":"2010","unstructured":"Liptan GL (2010) Fascia: a missing link in our understanding of the pathology of fibromyalgia. J Bodyw Mov Ther 14(1):3\u201312. https:\/\/doi.org\/10.1016\/j.jbmt.2009.08.003","journal-title":"J Bodyw Mov Ther"},{"issue":"8","key":"7846_CR42","first-page":"1888","volume":"28","author":"R P\u00f6yhi\u00e4","year":"2001","unstructured":"P\u00f6yhi\u00e4 R, Da Costa D, Fitzcharles MA (2001) Previous pain experience in women with fibromyalgia and inflammatory arthritis and nonpainful controls. J Rheumatol 28(8):1888\u20131891","journal-title":"J Rheumatol"},{"issue":"5","key":"7846_CR43","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/j.1468-1331.2011.03528.x","volume":"19","author":"DD Mitsikostas","year":"2012","unstructured":"Mitsikostas DD, Chalarakis NG, Mantonakis LI, Delicha E\u2010, Sfikakis PP (2012) Nocebo in fibromyalgia: meta\u2010analysis of placebo\u2010controlled clinical trials and implications for practice. Eur J Neurol 19(5):672\u2013680. https:\/\/doi.org\/10.1111\/j.1468-1331.2011.03528.x","journal-title":"Eur J Neurol"},{"key":"7846_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2019.10.001","volume":"17","author":"S Watson","year":"2019","unstructured":"Watson S, Caster O, Rochon PA, den Ruijter H (2019) Reported adverse drug reactions in women and men: aggregated evidence from globally collected individual case reports during half a century. EClinMed 17:100188. https:\/\/doi.org\/10.1016\/j.eclinm.2019.10.001","journal-title":"EClinMed"},{"issue":"11","key":"7846_CR45","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.43848","volume":"5","author":"F Gedin","year":"2022","unstructured":"Gedin F, Blom\u00e9 S, Pont\u00e9n M, Lalouni M, Fust J, Raquette A et al (2022) Placebo response and media attention in randomized clinical trials assessing cannabis-based therapies for pain. JAMA Netw Open 5(11):e2243848. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.43848","journal-title":"JAMA Netw Open"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07846-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07846-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07846-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T09:53:39Z","timestamp":1771581219000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07846-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["7846"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07846-6","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"15 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Provided by South West\u2013Central Bristol Research Ethics Committee (Reference: 22\/SW\/0145).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All study participants gave formal, informed, and written consent, preceding their consecutive enrollment into the database.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"Madhur Varadpande is a medical student at Imperial College London. Madhur Varadpande has no shareholdings in pharmaceutical companies.Simon Erridge is a resident doctor and Research Director at Curaleaf Clinic. Simon Erridge is a research fellow at Imperial College London. Simon Erridge has no shareholdings in pharmaceutical companies.Arushika Aggarwal is a medical student at Imperial College London. Arushika Aggarwal has no shareholdings in pharmaceutical companies.Evonne Clarke is the Patient Care Director at Curaleaf Clinic. Evonne Clarke has no shareholdings in pharmaceutical companies.Katy McLachlan is the Chief Pharmacist at Curaleaf Clinic. Katy McLachlan has no shareholdings in pharmaceutical companies.Ross Coomber is a consultant orthopaedic surgeon at St George\u2019s Hospital, London, and Operations Director at Curaleaf Clinic. Ross Coomber has no shareholdings in pharmaceutical companies.Shelley Barnes is a consultant pain specialist at Curaleaf Clinic. Shelley Barnes has no shareholdings in pharmaceutical companies.Alia Darweish Medniuk is a consultant pain specialist at Curaleaf Clinic. Alia Darweish Medniuk has no shareholdings in pharmaceutical companies.Rahul Guru is a consultant pain specialist at Curaleaf Clinic. Rahul Guru has no shareholdings in pharmaceutical companies.Wendy Holden is a consultant rheumatologist and pain specialist at Curaleaf Clinic. Wendy Holden has no shareholdings in pharmaceutical companies.Mohammed Sajad is a consultant pain specialist at Curaleaf Clinic. Mohammed Sajad has no shareholdings in pharmaceutical companies.Robert Seale is a consultant pain specialist at Curaleaf Clinic. Robert Seale has no shareholdings in pharmaceutical companies.Azfer Usmani is a consultant pain specialist at Curaleaf Clinic. Azfer Usmani has no shareholdings in pharmaceutical companies.Sanjay Varma is a consultant pain specialist at Curaleaf Clinic. Sanjay Varma has no shareholdings in pharmaceutical companies.James Rucker is a consultant psychiatrist at Curaleaf Clinic. James Rucker is an honorary consultant psychiatrist at The South London & Maudsley NHS Foundation Trust, and an NIHR Clinician Scientist Fellow at the Centre for Affective Disorders at King\u2019s College London. James Rucker is funded by a fellowship (CS-2017\u201317-007) from the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. James Rucker leads the Psychedelic Trials Group at King\u2019s College London. King\u2019s College London receives grant funding from COMPASS Pathways PLC to undertake phase 1 and phase 2 trials with psilocybin. COMPASS Pathways PLC has paid for James Rucker to attend trial-related meetings and conferences to present the results of research using psilocybin. James Rucker has undertaken paid consultancy work for Beckley PsyTech and Clerkenwell Health. Payments for consultancy work are received and managed by King\u2019s College London, and James Rucker does not benefit personally. James Rucker has no shareholdings in pharmaceutical companies.Michael Platt is a consultant in pain services at Curaleaf Clinic. Michael Platt has no shareholdings in pharmaceutical companies.Mikael Sodergren is a consultant hepatopancreatobiliary surgeon at Imperial College NHS Trust, London, a senior clinical lecturer at Imperial College London, and the chief medical officer of Curaleaf International. Mikael Sodergren has no shareholdings in pharmaceutical companies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations of interest statement"}}]}}